AR008799A1 - VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT - Google Patents

VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT

Info

Publication number
AR008799A1
AR008799A1 ARP970103502A ARP970103502A AR008799A1 AR 008799 A1 AR008799 A1 AR 008799A1 AR P970103502 A ARP970103502 A AR P970103502A AR P970103502 A ARP970103502 A AR P970103502A AR 008799 A1 AR008799 A1 AR 008799A1
Authority
AR
Argentina
Prior art keywords
composition
treatment
prophylaxis
prevent
treat malaria
Prior art date
Application number
ARP970103502A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR008799A1 publication Critical patent/AR008799A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion de vacuna que se emplea en la prevencion o tratamiento del paludismo, que comprende de numerosos antígenos derivados del paludismo encombinacion con un adyuvante, preferentemente un estimulador de la respuesta celular THI.También se propone la utilizacion de dicha vacuna para lapreparacion de medicamentos y métodos terapéuticos o preventivos aplicando dicha composicion.A vaccine composition for use in the prevention or treatment of malaria, comprising of numerous antigens derived from malaria in combination with an adjuvant, preferably a stimulator of cellular THI response. The use of said vaccine for the preparation of drugs and therapeutic or preventive methods applying said composition.

ARP970103502A 1996-08-02 1997-08-01 VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT AR008799A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9616351.4A GB9616351D0 (en) 1996-08-02 1996-08-02 Vaccine composition

Publications (1)

Publication Number Publication Date
AR008799A1 true AR008799A1 (en) 2000-02-23

Family

ID=10797980

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970103502A AR008799A1 (en) 1996-08-02 1997-08-01 VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT

Country Status (32)

Country Link
US (2) US20020172692A1 (en)
EP (2) EP0957933B1 (en)
JP (1) JP2000517295A (en)
KR (1) KR20000029747A (en)
CN (1) CN1241639C (en)
AP (1) AP1166A (en)
AR (1) AR008799A1 (en)
AT (1) ATE394119T1 (en)
AU (1) AU706303B2 (en)
BG (1) BG63290B1 (en)
BR (1) BR9710913A (en)
CA (1) CA2262402A1 (en)
CO (1) CO4650186A1 (en)
CZ (1) CZ290826B6 (en)
DE (1) DE69738672D1 (en)
DZ (1) DZ2283A1 (en)
EA (1) EA002167B1 (en)
GB (1) GB9616351D0 (en)
ID (1) ID17860A (en)
IL (1) IL128318A (en)
MA (1) MA24291A1 (en)
MY (1) MY116128A (en)
NO (1) NO319844B1 (en)
OA (1) OA10969A (en)
PE (1) PE97298A1 (en)
PL (1) PL188741B1 (en)
SK (1) SK282438B6 (en)
TR (1) TR199900195T2 (en)
UA (1) UA68336C2 (en)
UY (1) UY24654A1 (en)
WO (1) WO1998005355A1 (en)
ZA (1) ZA976815B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
WO2004037189A2 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
KR101176673B1 (en) * 2003-12-01 2012-08-23 가부시키가이샤 메이지 Peptide inhibiting angiotensin converting enzyme
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EA014314B1 (en) * 2005-08-02 2010-10-29 Новартис Вэксинес Энд Дайэгностикс Срл Reducing interference between oil-containing adjuvants and surfactant-containing antigens
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
EP2040743B1 (en) 2006-07-18 2013-10-02 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
PL2066344T3 (en) 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Inactivated Poliovirus combination vaccine
CL2008002361A1 (en) 2007-08-13 2009-08-07 Glaxosmithkline Biologicals Sa Use of an antigen derived from plasmodium falciparum circumesporozoite (cs) protein that is expressed in the preerythrocytic stage of malaria infection to treat babies against malaria.
US20100272745A1 (en) * 2007-12-21 2010-10-28 Dominique Ingrid Lemoine Vaccines for malaria
KR20100111281A (en) * 2007-12-24 2010-10-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines for malaria
WO2010002818A2 (en) * 2008-06-30 2010-01-07 United States Army As Represented By The Secretar Of The Army Malaria vaccine of self-assembling polypeptide nanoparticles
EP3351266A1 (en) * 2009-11-05 2018-07-25 The United States of America as represented by the Secretary of the Navy Plasmodium falciparum sporozoite and liver stage antigens
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (en) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 Application of Rapamycin as vaccine adjuvant and preparation method thereof
BR112019011286A2 (en) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa methods for producing a liposome composition, for preparing a vaccine composition and for preparing a vaccine kit.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87413B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071705B1 (en) * 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
PT82282B (en) * 1985-03-28 1988-02-17 Univ New York PREPARATION PROCESS OF AN IMMUNOGENIC SUPPORT-ANTIGEN PROTEIN CONJUGATE FOR USE AS A VACCINE AGAINST MALARIA
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9012580D0 (en) * 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
FR2679776A1 (en) * 1991-07-31 1993-02-05 Pasteur Institut Mixture of peptide constituents having vaccinating properties against malaria, in particular caused by Plasmodium falciparum
DK0614465T3 (en) * 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybrid protein between CS from Plasmodium and HBsAg
US6169171B1 (en) * 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
JP3755890B2 (en) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Adjuvant-containing vaccine composition
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM368994A0 (en) * 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
FR2744723A1 (en) * 1996-02-14 1997-08-14 Pasteur Institut RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF AN MSP-1 PROTEIN FROM A PLASMODIUM INFECTIOUS TO MAN FOR THE PRODUCTION OF ANTI-MALARIA VACCINES
FR2744724B1 (en) * 1996-02-14 2002-08-02 Pasteur Institut RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF PROTEIN MSP-1 OF A PLASMODIUM INFECTIOUS TO MAN FOR THE PRODUCTION OF ANTI-MALARIA VACCINES

Also Published As

Publication number Publication date
WO1998005355A1 (en) 1998-02-12
IL128318A (en) 2002-04-21
SK282438B6 (en) 2002-02-05
EP1623720A2 (en) 2006-02-08
EP0957933B1 (en) 2008-05-07
SK11599A3 (en) 2000-03-13
IL128318A0 (en) 2000-01-31
AP1166A (en) 2003-06-30
JP2000517295A (en) 2000-12-26
EA199900069A1 (en) 1999-10-28
ZA976815B (en) 1998-05-11
EP1623720A3 (en) 2006-02-22
BG103141A (en) 1999-08-31
KR20000029747A (en) 2000-05-25
PL331424A1 (en) 1999-07-19
MA24291A1 (en) 1998-04-01
CO4650186A1 (en) 1998-09-03
CN1231613A (en) 1999-10-13
CZ290826B6 (en) 2002-10-16
US20020172692A1 (en) 2002-11-21
PE97298A1 (en) 1999-02-14
AP9901448A0 (en) 1999-03-31
EA002167B1 (en) 2002-02-28
AU4204097A (en) 1998-02-25
ATE394119T1 (en) 2008-05-15
PL188741B1 (en) 2005-04-29
MY116128A (en) 2003-11-28
CA2262402A1 (en) 1998-02-12
BR9710913A (en) 1999-08-17
TR199900195T2 (en) 1999-04-21
BG63290B1 (en) 2001-09-28
AU706303B2 (en) 1999-06-10
ID17860A (en) 1998-01-29
CZ29299A3 (en) 1999-06-16
UA68336C2 (en) 2004-08-16
EP0957933A1 (en) 1999-11-24
DE69738672D1 (en) 2008-06-19
GB9616351D0 (en) 1996-09-11
NO990464L (en) 1999-02-01
OA10969A (en) 2003-03-04
NO319844B1 (en) 2005-09-19
DZ2283A1 (en) 2002-12-25
UY24654A1 (en) 2001-08-27
CN1241639C (en) 2006-02-15
NO990464D0 (en) 1999-02-01
US20060292170A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
AR008799A1 (en) VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT
TR200101481T2 (en) Cancer treatment composition and method using natural herbal essential oils.
ES2196024T3 (en) CONJUGATED VACCINES OF GANGLIOSIDO-KLH WITH QS-21.
ES2191152T3 (en) COMBINED THERAPY FOR THE TREATMENT OF PSYCHOSIS.
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
AR023715A1 (en) PHARMACEUTICAL COMPOSITION FOR A SUBJECT WHO NEEDS AN ELEVATION OF THE CONTENT OF NAD INTRACELLULAR, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE TO INCREASE THE PROTECTIVE CELLULAR RESPONSES TO GENOTOXIC STRESS IN THE SKIN
BR9610679A (en) Leishmania antigens for use in leishmaniasis therapy and dysgnosis
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
EP1471936A4 (en) Hiv vaccine and method of use
BG104092A (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
NO984760L (en) Use of an osmolyte in the treatment of effects caused by an infection, inflammation or immune dysfunction
ES2177535T3 (en) VACCINES AGAINST INTESTINAL PROTOZES.
ES2194104T3 (en) USE OF SELEGYLINE FOR THE TREATMENT OF LOSS OF HEARING IN MAMMALS.
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AR015956A1 (en) COMPOSITIONS OF OROMUCOSAL CYTOKINS AND USES OF THE SAME
NO20012634D0 (en) New cancer treatments
AR003001A1 (en) PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
AR010568A1 (en) POLYPEPTIDE, VACCINE COMPOSITION, USE OF POLYPEPTIDE IN THE MANUFACTURE OF A COMPOSITION, AND METHOD TO PRODUCE AN IMMUNO-PROTECTIVE RESPONSE AGAINST HELICOBACTER PYLORI INFECTION
ES2158857T3 (en) STREPTOQUINASE-BASED VACCINES.
MX9201258A (en) COMPOUNDS FOR THE TREATMENT OF CANCER AND PROCEDURE FOR ITS PREPARATION.
IT1277926B1 (en) USE OF NATURAL CYTOKINE MUTEINS AS IMMUNOGENS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO TREAT OR PREVENT
YU37402A (en) Vaccine for healing prostate inflammation and benign prostate hyperplasia, that includes lactobacillus layers
NO953311D0 (en) Use of anti-helminth vaccines in the control of parasitic disease in connection with loss of natural immunity
ZA893310B (en) Novel strobilurine derivatives,their preparation and their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal